Literature DB >> 1830459

Tissue- and species-specific differences in ligand binding to thromboxane A2 receptors.

G W Dorn1.   

Abstract

The ligand binding site of vascular smooth muscle (VSM) and platelet thromboxane A2 (TxA2) receptors was characterized in humans and rabbits using the TxA2 mimetic [125I]BOP. Vessel contraction and platelet aggregation studies demonstrated that unlabeled I-BOP and the prostaglandin H2 (PGH2) mimetic U-46619 were potent agonists in rabbit aortas, human saphenous veins, and washed human and rabbit platelets. [125I]BOP bound saturably to a single site on cultured vascular smooth muscle (VSM) cells from rabbit aortas and human saphenous veins with dissociation constants (Kd) of 392 +/- 8 (n = 5) and 390 +/- 120 pM (n = 6) and binding capacities (Bmax) of 5,322 +/- 200 and 2,017 +/- 322 sites/cell, respectively. [125I]BOP also bound saturably to one site on rabbit platelets (Kd = 415 +/- 15 pM, Bmax = 594 +/- 43 sites/platelet, n = 4) but, in agreement with previous studies, to two sites on human platelets (high-affinity Kd = 118 +/- 24 pM, Bmax = 121 +/- 33 sites/platelet; low-affinity Kd = 1.1 +/- 0.47 nM, Bmax 232 +/- 23 sites/platelet, n = 4). [125I]BOP was displaced from its binding site on rabbit and human VSM and platelets by stable TxA2/PGH2 analogues possessing either agonist or antagonist activity but not by other prostaglandins. The rank orders of the binding inhibition constants (IC50) for the TxA2/PGH2 analogues were compared among the four tissues and were highly correlated (r = 0.963) in VSM and platelets from rabbits but not humans (r = 0.699), suggesting that human VSM TxA2 receptors may be distinct from platelet TxA2 receptors. The IC50 rank order was also highly correlated (r = 0.935) between human and rabbit platelets.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1830459     DOI: 10.1152/ajpregu.1991.261.1.R145

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  4 in total

1.  Characterization of excitatory prostanoid receptors in the human umbilical artery in vitro.

Authors:  J I Boersma; K M Janzen; L Oliveira; D J Crankshaw
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 2.  A Review of Prostanoid Receptors: Expression, Characterization, Regulation, and Mechanism of Action.

Authors:  Roger G Biringer
Journal:  J Cell Commun Signal       Date:  2020-09-24       Impact factor: 5.782

3.  Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan.

Authors:  S D Katugampola; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

4.  Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.

Authors:  S Ohkubo; N Nakahata; Y Ohizumi
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.